Thiostrepton, USP

Thiostrepton is a bactericidal macrocyclic thiopeptide antibiotic that is produced by Streptomyces azureus and was originally detailed by Donovick et al. in 1955. Thiostrepton shows broad activity against both gram-positive and gram-negative bacteria, as well as anti-plasmodial effects.
Thiostrepton inhibits prokaryotic translation by inhibiting ribosome turnover after the elongation step in protein synthesis by inhibiting both the dissociation of elongation factor G (EF-G) from the ribosome and the release of inorganic phosphate from EF-G following GTP hydrolysis. Thiostrepton has also been shown to inhibit the binding of elongation factor 4 (EF4) to the 70S ribosome.
Thiostrepton has been shown to inhibit the oncogenic transcription factor FoxM1 and is cytotoxic to malignant mesothelioma cells in a dose dependent fashion.
Thiostrepton conforms to United States Pharmacopeia specifications.

Please contact us at for specific academic pricing.

Background

Thiostrepton inhibits prokaryotic translation by inhibiting ribosome turnover after the elongation step in protein synthesis by inhibiting both the dissociation of elongation factor G (EF-G) from the ribosome and the release of inorganic phosphate from EF-G following GTP hydrolysis. Thiostrepton has also been shown to inhibit the binding of elongation factor 4 (EF4) to the 70S ribosome.